Spero Therapeutics news centers on its work as a clinical-stage biopharmaceutical company focused on immunology and inflammation. Company updates often address SP001, its third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease.
Other important Spero news relates to Utebzi, the Spero-developed oral antibiotic licensed to GSK for most territories and to Meiji for certain Asian territories. Updates may involve FDA-related disclosures, partner-linked commercialization rights, milestone and royalty arrangements, and financing backed by portions of future Utebzi payments.
Spero also issues news on quarterly operating results, business updates, healthcare conference presentations, executive and clinical leadership appointments, and inducement equity grants under Nasdaq listing rules. These categories reflect both its drug-development pipeline and its public-company reporting obligations.
Spero Therapeutics (Nasdaq: SPRO) granted equity awards to a new employee on November 2, 2026, as an employment inducement. The Compensation Committee approved 217,000 restricted stock units (RSUs) and 434,000 stock options under the amended 2019 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest 25% on the first anniversary of the vesting start date, with the remainder vesting in 36 equal monthly installments thereafter. The RSUs vest in four equal annual installments beginning on that first anniversary. Both awards require continued employment through the applicable vesting dates.
Spero Therapeutics (SPRO) will participate in the Guggenheim healthcare conference on November 10 and the Jefferies healthcare conference on November 18–19, 2026. CEO Esther Rajavelu will join a fireside chat at 10:30 AM ET at Guggenheim in Boston. Management will also be available for investor meetings at both conferences, with the Jefferies event taking place in London.
Spero Therapeutics (Nasdaq: SPRO) appointed Amy Rock as Chief Regulatory and Quality Officer and Dae Gon Ha as Senior Vice President, Corporate Development.
Rock will lead global regulatory strategy, quality and drug safety monitoring, supporting SP001's clinical development in IgG4-related disease and potential additional indications. Ha will lead investor relations strategy and business development, including evaluating opportunities to expand the immunology pipeline.
Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, after 11 years at Spero. His work included leading development of Utebzi, the company's legacy program licensed to GSK.
Spero Therapeutics (SPRO) will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026. President and CEO Esther Rajavelu will speak at 9:15 AM ET at the Lotte New York Palace in New York City. Leadership will also be available for one-on-one meetings. A webcast will be accessible through Spero's Events + Presentations webpage, with a replay available for approximately 90 days following the conference.
Spero Therapeutics (SPRO) granted equity awards to new employees on October 1, 2026, under its 2019 Inducement Equity Incentive Plan.
The Compensation Committee approved 233,000 restricted stock units (RSUs) and 323,000 stock options as employment inducements under Nasdaq Listing Rule 5635(c)(4). Shares underlying the options vest 25% on the first anniversary of each employee’s start date, with the remainder vesting in 36 equal monthly installments thereafter. RSUs vest in four equal annual installments beginning on that first anniversary. Both schedules require continued employment through the applicable vesting dates.
Spero Therapeutics (SPRO) granted equity awards to new employees under its 2019 Inducement Equity Incentive Plan, effective September 1, 2026.
The Compensation Committee approved an aggregate of 102,000 restricted stock units (RSUs) and 67,600 stock options as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The plan is used solely for individuals who were not previously employed by Spero, or rejoin after a bona fide break in service. Stock options vest 25% on September 1, 2027, with the balance vesting in 36 equal monthly installments thereafter, while RSUs vest in four equal annual installments starting September 1, 2027, in each case subject to continued employment and the plan and award agreements.
Spero Therapeutics (SPRO)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 15, 2026, at 1:30 PM ET.President and CEO Esther Rajavelu will deliver the company presentation, and Spero's leadership team will be available for one-on-one meetings. The presentation will be webcast, with access via Spero's website Events + Presentations page and a replay available for about 90 days.
Spero Therapeutics (Nasdaq: SPRO) reported second quarter 2026 results and major strategic milestones. Net loss was $9.6 million (vs. $1.7 million in Q2 2025), or $0.16 per diluted share. Total revenue was $0 compared with $14.2 million a year earlier, as prior collaboration and grant revenue was fully recognized in earlier periods.
Research and development expenses fell to $3.4 million from $10.7 million, mainly due to reduced Utebzi Phase 3 costs, while general and administrative expenses increased to $6.5 million from $5.9 million. Cash and cash equivalents were $50.8 million at June 30, 2026, excluding proceeds from a subsequent royalty financing.
Operationally, the FDA approved Utebzi, the first and only oral carbapenem for certain adult cUTI patients, with GSK holding U.S. and European commercialization rights. Spero also entered an exclusive license with Innovent Biologics for SP001 outside Greater China, closed a $105 million non-recourse, non-dilutive royalty financing backed by a portion of future Utebzi proceeds, and appointed Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer. The company expects its June 30 cash plus financing proceeds to fund operations into the second half of 2029.
Spero Therapeutics (Nasdaq: SPRO) announced that its Board Compensation Committee approved an inducement equity grant under the 2019 Inducement Equity Incentive Plan to a new employee. Effective August 3, 2026, the grant consists of 324,622 stock options and 162,311 restricted stock units (RSUs), made in accordance with Nasdaq Listing Rule 5635(c)(4), which permits equity awards as a material inducement to employment for individuals not previously employed by the company.
The stock options vest 25% on August 3, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued employment. The RSUs vest in four equal annual installments beginning August 3, 2027, also contingent on continued employment. Both the options and RSUs are governed by the terms of the 2019 Inducement Plan and the related award agreements.
Spero Therapeutics (Nasdaq: SPRO) will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, 2026, after market close. Management will hold a conference call and live audio webcast at 5:00 p.m. EDT to discuss results, business, and pipeline updates.
Investors can join by dialing 1-877-407-0789 (domestic) or 1-201-689-8562 (international) using conference ID 13762082, or via a webcast link available on the Investors page of the Spero website. An archived webcast will remain accessible for 30 days.